What the FDA Relabeling of Abacavir Means for You and Your Patients

In this presentation:

An FDA safety alert reported studies linking potentially fatal hypersensitivity reactions with abacavir, an HIV-antiretroviral medication, to a specific HLA-B allele (HLA-B*5701). Testing patients for this allele, prior to receiving abacavir, is now recommended. Dr. O’Kane and Dr. Yao discuss what this means for you and your patients.

View the presentation

Viewing Tips

• Before viewing, print the user-friendly Notes Pages.
• After viewing, obtain a Record of Viewing.

Related Tests

• #89346  HLA-B*5701 Genotype, Abacavir Hypersensitivity

Related Information

• Learn more about Dennis J. O'Kane, Ph.D.
• Learn more about the Division of Clinical Biochemistry & Immunology.
• Learn more about Joseph D. Yao, M.D.
• Learn more about the Division of Clinical Microbiology.

Send to a Colleague

We invite you to forward this presentation to a colleague.